Get the Stockscreener App
28.20
1.84%
-0.53
After Hours:
29.00
0.80
+2.84%
Immunovant Inc stock is traded at $28.20, with a volume of 377.03K.
It is down -1.84% in the last 24 hours and down -5.62% over the past month.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
See More
Previous Close:
$28.73
Open:
$28.81
24h Volume:
377.03K
Relative Volume:
0.43
Market Cap:
$4.14B
Revenue:
-
Net Income/Loss:
$-272.55M
P/E Ratio:
-14.61
EPS:
-1.93
Net Cash Flow:
$-243.55M
1W Performance:
+4.95%
1M Performance:
-5.62%
6M Performance:
-4.63%
1Y Performance:
-26.26%
1-Day Range:
$28.00
$28.98
1-Week Range:
$26.51
$29.10
52-Week Range:
$24.61
$45.58
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
28.20 | 4.14B | 0 | -272.55M | -243.55M | -1.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Algert Global LLC Sells 83,969 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Contrasting Immunovant (NASDAQ:IMVT) and enGene (NASDAQ:ENGN) - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Receives $48.10 Average Target Price from Analysts - Defense World
Have Immunovant Insiders Been Selling Stock? - Simply Wall St
Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Buy" by Brokerages - MarketBeat
KBC Group NV Purchases 612 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Connor Clark & Lunn Investment Management Ltd. Sells 56,789 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Trend Tracker for (IMVT) - Stock Traders Daily
Insider Selling: Immunovant, Inc. (NASDAQ:IMVT) Insider Sells 3,650 Shares of Stock - MarketBeat
Insider Selling: Immunovant, Inc. (NASDAQ:IMVT) CEO Sells 16,692 Shares of Stock - MarketBeat
Immunovant CEO Peter Salzmann sells shares for $424,811 By Investing.com - Investing.com South Africa
Immunovant CFO Eva Renee Barnett sells $106,228 in stock By Investing.com - Investing.com South Africa
Immunovant CEO Peter Salzmann sells shares for $424,811 - Investing.com
Immunovant CFO Eva Renee Barnett sells $106,228 in stock - Investing.com
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Victory Capital Management Inc. - Defense World
Victory Capital Management Inc. Has $9.56 Million Stake in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus - MSN
Immunovant stock hits 52-week low at $24.66 amid market shifts - Investing.com Nigeria
Principal Financial Group Inc. Purchases 391,436 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
(IMVT) Technical Data - Stock Traders Daily
FMR LLC's Strategic Acquisition of Immunovant Inc Shares - GuruFocus.com
Immunovant: Pipeline Progressing With One Minor Delay (NASDAQ:IMVT) - Seeking Alpha
Immunovant (NASDAQ:IMVT) Posts Earnings Results, Misses Expectations By $0.15 EPS - MarketBeat
Analysts Provide An Important Insights On Immunovant Inc (IMVT) - Stocks Register
Immunovant’s Strategic Advances in Autoimmune Therapies - TipRanks
Interesting IMVT Put And Call Options For March 2025 - Nasdaq
Immunovant's (IMVT) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Immunovant Inc (IMVT) Quarterly 10-Q Report - Quartzy
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 - The Manila Times
Immunovant Advances IMVT-1402 with 5 IND Clearances Despite Widening Losses | IMVT Stock News - StockTitan
Immunovant Breaks Above 200-Day Moving AverageBullish for IMVT - Nasdaq
Emerald Mutual Fund Advisers Trust Has $5.24 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Where are the Opportunities in (IMVT) - Stock Traders Daily
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Position Boosted by abrdn plc - MarketBeat
Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - MarketBeat
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - The Manila Times
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - ForexTV.com
Immunovant's chief medical officer sells $94,171 in stock By Investing.com - Investing.com Canada
Immunovant CTO Jay Stout sells $80,912 in stock By Investing.com - Investing.com Canada
Immunovant, Inc. (NASDAQ:IMVT) CTO Sells $80,912.20 in Stock - MarketBeat
Immunovant CTO Jay Stout sells $80,912 in stock - Investing.com India
Immunovant's chief medical officer sells $94,171 in stock - Investing.com India
Immunovant's chief legal officer Mark Levine sells shares worth $128,780 By Investing.com - Investing.com Australia
Immunovant's chief legal officer Mark Levine sells shares worth $128,780 - Investing.com
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):